Innovation for Health - 13 February 2020
Contact Investor Forum I4H Bootcamp
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare

Tim Knotnerus

CEO, AgomAb Therapeutics

 

AgomAb Therapeutics is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. In April 2019, a 21 million euros financing round was raised. Prior to AgomAb Therapeutics, Tim was VP Corporate Development at AM-Pharma where he was responsible for Corporate and Business Development of the company. In that capacity he co-led the $600M option-to-acquisition deal between Pfizer and AM-Pharma. Prior to that, Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies, where he was instrumental in the financing and support of various portfolio companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).
Dharminder Chalal
SkylineDx
Marcel Levi
University College London Hospitals
Michel Dumontier
Maastricht University
Thijn Brummelkamp
Scenic Biotech
Hans Schikan
Topsector Life Sciences & Health
Inge Huitinga
Netherlands Brain Bank
Sjaak Vink
TheSocialMedwork
Annemarie Jorritsma
NVP
Wiro Niessen
Erasmus MC, TU Delft & Quantib
Tim Knotnerus
AgomAb Therapeutics
Elise Meijer
Antwerp Management School & Accenture Strategy
Esther Talboom-Kamp
Saltro Diagnostics
Joep Muijrers
PureTech Health
Els Beirnaert
Aelin Therapeutics
Carine van den Brink
Axon Lawyers

Claudia Rijcken
pharmi

Rajiv Vaid Basaiawmoit
Aarhus University & Biosymfonix
Sponsors & Partners 2020
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
AXON Lawyers
Media sponsor
Powered by
Hyphen Projects
© 2019 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.